NewAmsterdam Pharma Q3 EPS $(0.61) Misses $(0.41) Estimate, Sales $348.000K Miss $5.287M Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.41) by 47.34 percent. This is a 238.89 percent decrease over losses of $(0.18) per share